Publications by authors named "Herishanu Y"

Article Synopsis
  • * In the phase 2 trial, 20 patients received anti-CD19 CAR-T therapy combined with nivolumab, which was found to be safe; results showed an impressive 84% overall response rate and notable progression-free and overall survival rates at both 6 and 12 months.
  • * Although CAR-T cell expansion was similar in patients eligible and ineligible for nivolumab, those eligible had a higher proportion of specific beneficial immune cell types, indicating that further
View Article and Find Full Text PDF

Background: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment.

View Article and Find Full Text PDF

Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with chronic lymphocytic leukemia (CLL) have a significantly heightened risk of developing other malignancies (OMs), with a study tracking nearly 20,000 CLL patients revealing 3,513 OMs diagnosed over 129,254 years of follow-up.
  • The study found that treatment with fludarabine and cyclophosphamide increased the likelihood of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), while non-melanoma skin cancer (NMSC) and prostate cancer were common solid tumors in treated patients.
  • Importantly, patients with CLL who developed OMs had lower overall survival rates, especially those diagnosed with AML and MDS, highlighting that C
View Article and Find Full Text PDF

In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19.

View Article and Find Full Text PDF

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria.

View Article and Find Full Text PDF

Patients with chronic lymphocytic leukaemia (CLL) infected with SARS-CoV-2 are at increased risk of severe COVID-19 and death. The outcomes of CLL patients with COVID-19 during the omicron subvariants and in particular with BA.5 are not fully elucidated.

View Article and Find Full Text PDF

Chimeric antigen receptor T-cells (CAR-T) are widely used for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL). The data for CAR-T cell therapy in patients with extra-nodal (EN) lymphoma is restricted. We included 126 consecutive patients with DLBCL treated with commercially available CAR-T cells (tisagenlecleucel, n = 100, 79.

View Article and Find Full Text PDF

Electrophiles for covalent inhibitors that are suitable for in vivo administration are rare. While acrylamides are prevalent in FDA-approved covalent drugs, chloroacetamides are considered too reactive for such purposes. We report sulfamate-based electrophiles that maintain chloroacetamide-like geometry with tunable reactivity.

View Article and Find Full Text PDF

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19.

Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries.

View Article and Find Full Text PDF

Most chronic lymphocytic leukemia (CLL) clones express B-cell receptors (BcR) of both IgM/IgD isotypes; however, 5%-10% of CLL cases express isotype-switched immunoglobulin G (IgG). The early signaling and spatial patterning of the various BcRs at steady state and after activation are still fully unresolved. Herein, we show higher expression of the BcR signalosome elements and a more robust constitutive cell-intrinsic proximal BcR signaling in CLL with unmutated IGHV expressing IgM isotype (IgM U-CLL), compared with IGHV-mutated CLL (M-CLL) expressing either IgM or IgG isotypes.

View Article and Find Full Text PDF

Importance: Patients with cancer have an increased risk of severe disease and mortality from COVID-19, as the disease and antineoplastic therapy cause reduced vaccine immunogenicity. Booster doses have been proposed to enhance protection, and efficacy data are emerging from several studies.

Objective: To evaluate the proportion of COVID-19 primary vaccination non-responders with cancer who seroconvert after a booster dose.

View Article and Find Full Text PDF

Patients with lymphoproliferative diseases are at high risk for SARS-CoV-2-related complications and mortality. The role of casirivimab and imdevimab (REGEN-COV), a neutralizing antibody cocktail, to treat immunocompromised hemato-oncological patients with SARS-CoV-2 disease 2019 (Covid-19) remains unknown. Here, we present our clinical experience on the outcome of 15 hematological patients treated with REGEN-COV for SARS-CoV-2 infection.

View Article and Find Full Text PDF

Objectives: The recent surge in coronavirus disease 2019 cases led to the consideration of a booster vaccine in previously vaccinated immunosuppressed individuals. However, the immunogenic effect of a third-dose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in immunosuppressed patients is still unknown.

Methods: This was an observational cohort study of 279 previously vaccinated immunosuppressed patients followed at a single tertiary hospital in Israel.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of F-fluorodeoxyglucose ([F]FDG) PET-CT in staging and predicting progression-free survival (PFS) in patients with newly diagnosed mucosa-associated lymphoid tissue (MALT) lymphoma.
  • It analyzes data from 66 studies, finding that PET scans detected extranodal lesions in over half of the cases, with detection rates differing based on lesion location and tissue characteristics.
  • Higher SUVmax measurements of extranodal lesions were associated with shorter PFS, indicating that [F]FDG PET-CT can be a valuable tool in assessing the severity and prognosis of MALT lymphoma.
View Article and Find Full Text PDF
Article Synopsis
  • - Polatuzumab (Pola)-based regimens and CAR T cells result in better outcomes than traditional chemoimmunotherapy for patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL), but there's debate on which is more effective.
  • - A retrospective study compared the efficacy of CAR T therapy to Pola-rituximab and Pola-bendamustine in patients who had undergone at least two prior treatments, using propensity score matching for accurate comparison.
  • - Results showed that CAR T had higher overall (83% vs. 66%) and complete response rates (58% vs. 44%), and significantly longer progression-free survival (PFS) and overall survival (OS
View Article and Find Full Text PDF

This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with chronic lymphocytic leukemia (CLL) show a significantly impaired ability to generate antibodies after COVID-19 vaccination, particularly after a standard two-dose series.
  • In a study evaluating responses to a third mRNA vaccine dose, only 23.8% of 172 CLL patients demonstrated an antibody response, with lower rates among those actively undergoing treatment.
  • Factors associated with a better response included being off active therapy and having higher levels of serum immunoglobulin A, highlighting the challenges faced by patients on treatments like BTK inhibitors or anti-CD20 antibodies.
View Article and Find Full Text PDF